Our thought leadership in action
Explore some of our expert contributions, posters and related content that showcased our commitment to help commercialization challenges for our partners and patients they serve.
Missed us at ISPOR 2025? Connect with our experts to learn more
Educational symposia
Bringing us together or pushing us apart: Will JCA, HEMA, and other cross-border collaboration initiatives improve patient access?
Moderator: Erika Wissinger, Cencora
Panelists: Jon Campbell, National Pharmaceutical Council; Michael Drummond, University of York; Eldon Spackman, University of Calgary
Panelists: Jon Campbell, National Pharmaceutical Council; Michael Drummond, University of York; Eldon Spackman, University of Calgary
With team across North America, Europe, and Japan, we blend global reach with local expertise
3,000
Consultants worldwide
30+
Global markets covered
235+
Brands represented
Innomar Strategies
Ensuring commercialization success in Canada
For Canadian healthcare market access challenges, InnomarConsulting™ provides solutions across the product lifecycle through unparalleled relationships and valued expertise. By partnering with our team, you help ensure the success of your launch, maximize patient access, improve sales performance, and extend brand relevancy. We help existing manufacturers, as well as those new to Canada, to develop and execute effective commercialization strategies, ensuring patients efficiently gain access to the latest advances in healthcare.
Explore our poster presentations at ISPOR 2025
- An evaluation of PhlexNeuron, an internal, proprietary artificial intelligence (AI) tool for systematic literature review (SLR) screening
- Analysis of the effect of Trofinetide treatment on the domain and item-level responses of the Rett syndrome behavior questionnaire using data from the LAVENDER trial
- Broadening the scope of value: Evaluating payer perspectives and insights on ICER’s latest initiatives and tools
Cost-effectiveness analyses of Repotrectinib in TKI-naïve patients with ROS1+ advanced non-small cell lung cancer
- Developing a Large Language Model-Based Simulation for P&T Committees: Methodology and Inputs for Realistic Dynamics
- Inclusion of health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in the United States Food and Drug Administration (FDA) labels
- Leveraging artificial intelligence to streamline study quality assessment in systematic literature reviews
Payer perceptions on creating a national value assessment body in the US
- Payer perspectives on ICER Evidence Reports: Insights into utility for coverage and formulary decision-making
- Staffing resource use: a cost impact model for the utilization and implementation of medications for opioid use disorder within US jails and prisons
* Available in English only.
Cencora partners with ISPOR to advance HEOR
We are thrilled to announce Cencora's partnership with ISPOR in their new Corporate Partnership Program! This collaboration aligns with our commitment to advancing health economics and outcomes research. Together, we'll drive innovation, enhance global health outcomes, and strengthen the HEOR community.
Catch up on our latest insights
Catch up on the latest edition of HTA Quarterly
In this edition, following the implementation of the European Union (EU) Regulation on Health Technology Assessment (HTAR) for medicinal products in January, we review current processes and prepare for upcoming guidance for medical devices. We also discuss the value of early network mapping in systemic literature reviews (SLRs) for health technology assessment (HTA) submissions and spotlight the improved drug pricing environment in Japan, a result of positive changes to the pricing system adopted in April 2024.
Navigating the Canadian reimbursement landscape
Despite perceptions of a universal healthcare system, Canada’s medication reimbursement relies on both public and private payers, impacting market access for new therapies. In this video, Beth Koster, Director, Health Economics & Outcomes Research (HEOR), shares considerations for market access, including the need for early strategic planning and comprehensive evidence collection.
Connect with our team
Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.
